Breadth and function of antibody response to acute SARS-CoV-2 infection in humans
Abstract Serological and plasmablast responses and plasmablast-derived IgG monoclonal antibodies (MAbs) have been analysed in three COVID-19 patients with different clinical severities. Potent humoral responses were detected within 3 weeks of onset of illness in all patients and the serological titre was elicited soon after or concomitantly with peripheral plasmablast response. An average of 13.7% and 13.0% of plasmablast-derived MAbs were reactive with virus spike glycoprotein or nucleocapsid, respectively. A subset of anti-spike (10 of 32) and over half of anti-nucleocapsid (19 of 35) antibodies cross-reacted with other betacoronaviruses tested and harboured extensive somatic mutations, indicative of an expansion of memory B cells upon SARS-CoV-2 infection. Fourteen of 32 anti-spike MAbs, including five anti-RBD, three anti-non-RBD S1 and six anti-S2, neutralised wild-type SARS-CoV-2 in independent assays. Anti-RBD MAbs were further grouped into four cross-inhibiting clusters, of which six antibodies from three separate clusters blocked the binding of RBD to ACE2 and five were neutralising. All ACE2-blocking anti-RBD antibodies were isolated from two patients with prolonged fever, which is compatible with substantial ACE2-blocking response in their sera. At last, the identification of non-competing pairs of neutralising antibodies would offer potential templates for the development of prophylactic and therapeutic agents against SARS-CoV-2..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
bioRxiv.org - (2020) vom: 21. Okt. Zur Gesamtaufnahme - year:2020 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Huang, Kuan-Ying A. [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
doi: |
10.1101/2020.08.28.267526 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI018640338 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI018640338 | ||
003 | DE-627 | ||
005 | 20230429090634.0 | ||
007 | cr uuu---uuuuu | ||
008 | 200831s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2020.08.28.267526 |2 doi | |
035 | |a (DE-627)XBI018640338 | ||
035 | |a (DE-599)biorXiv10.1101/2020.08.28.267526 | ||
035 | |a (biorXiv)10.1101/2020.08.28.267526 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 570 |q DE-84 | |
100 | 1 | |a Huang, Kuan-Ying A. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Breadth and function of antibody response to acute SARS-CoV-2 infection in humans |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Serological and plasmablast responses and plasmablast-derived IgG monoclonal antibodies (MAbs) have been analysed in three COVID-19 patients with different clinical severities. Potent humoral responses were detected within 3 weeks of onset of illness in all patients and the serological titre was elicited soon after or concomitantly with peripheral plasmablast response. An average of 13.7% and 13.0% of plasmablast-derived MAbs were reactive with virus spike glycoprotein or nucleocapsid, respectively. A subset of anti-spike (10 of 32) and over half of anti-nucleocapsid (19 of 35) antibodies cross-reacted with other betacoronaviruses tested and harboured extensive somatic mutations, indicative of an expansion of memory B cells upon SARS-CoV-2 infection. Fourteen of 32 anti-spike MAbs, including five anti-RBD, three anti-non-RBD S1 and six anti-S2, neutralised wild-type SARS-CoV-2 in independent assays. Anti-RBD MAbs were further grouped into four cross-inhibiting clusters, of which six antibodies from three separate clusters blocked the binding of RBD to ACE2 and five were neutralising. All ACE2-blocking anti-RBD antibodies were isolated from two patients with prolonged fever, which is compatible with substantial ACE2-blocking response in their sera. At last, the identification of non-competing pairs of neutralising antibodies would offer potential templates for the development of prophylactic and therapeutic agents against SARS-CoV-2. | ||
700 | 1 | |a Tan, Tiong Kit |e verfasserin |4 aut | |
700 | 1 | |a Chen, Ting-Hua |e verfasserin |4 aut | |
700 | 1 | |a Huang, Chung-Guei |e verfasserin |4 aut | |
700 | 1 | |a Harvey, Ruth |e verfasserin |4 aut | |
700 | 1 | |a Hussain, Saira |e verfasserin |4 aut | |
700 | 1 | |a Chen, Cheng-Pin |e verfasserin |4 aut | |
700 | 1 | |a Harding, Adam |e verfasserin |4 aut | |
700 | 1 | |a Gilbert-Jaramillo, Javier |e verfasserin |4 aut | |
700 | 1 | |a Liu, Xu |e verfasserin |4 aut | |
700 | 1 | |a Knight, Michael |e verfasserin |4 aut | |
700 | 1 | |a Schimanski, Lisa |e verfasserin |4 aut | |
700 | 1 | |a Shih, Shin-Ru |e verfasserin |4 aut | |
700 | 1 | |a Lin, Yi-Chun |e verfasserin |4 aut | |
700 | 1 | |a Cheng, Chien-Yu |e verfasserin |4 aut | |
700 | 1 | |a Cheng, Shu-Hsing |e verfasserin |4 aut | |
700 | 1 | |a Huang, Yhu-Chering |e verfasserin |4 aut | |
700 | 1 | |a Lin, Tzou-Yien |e verfasserin |4 aut | |
700 | 1 | |a Jan, Jia-Tsrong |e verfasserin |4 aut | |
700 | 1 | |a Ma, Che |e verfasserin |4 aut | |
700 | 1 | |a James, William |e verfasserin |4 aut | |
700 | 1 | |a Daniels, Rodney S. |e verfasserin |4 aut | |
700 | 1 | |a McCauley, John W. |e verfasserin |4 aut | |
700 | 1 | |a Rijal, Pramila |e verfasserin |4 aut | |
700 | 1 | |a Townsend, Alain R. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 21. Okt. |
773 | 1 | 8 | |g year:2020 |g day:21 |g month:10 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.08.28.267526 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2020 |b 21 |c 10 | ||
953 | |2 045F |a 570 |